![Piperidine,3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-1-methyl-,(3S,4R)-](https://static.cymitquimica.com/products/IN/img/DA00IMIM.png "Cliquez pour agrandir")
Piperidine,3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-1-methyl-,(3S,4R)-
CAS : 110429-36-2
Ref. IN-DA00IMIM
| 1g | Arrêté | ||
| 5g | Arrêté | ||
| 10g | Arrêté | ||
| 25g | Arrêté | ||
| 10mg | Arrêté | ||
| 100mg | Arrêté | ||
| 250mg | Arrêté |
Informations sur le produit
Nom :
Piperidine,3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-1-methyl-,(3S,4R)-
Synonymes :
- [u'N-Methylparoxetine', u'110429-36-2', u'N-Methyl Paroxetine', u'Methylparoxetine', u'UNII-3X658583PO', u'3X658583PO', u'CPD000469181', u'(3S,4R)-3-[(1,3-Benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-1-methylpiperidine', u'PubChem15206', u'MLS001424004', u'Paroxetine Related Compound F', u'(3S,4R)-N-Methylparoxetine', u'CHEMBL322363', u'CHEBI:94536', u'DTXSID20149243', u'MOJZPKOBKCXNKG-YJBOKZPZSA-N', u'HMS2051I12', u'BCP13507', u'ZINC2586028', u'CM0167', u'MFCD03788781', u'AKOS015851047', u'AKOS015889696', u'CCG-100867', u'NC00117', u'AC-18943', u'SAM001246633', u'SMR000469181', u"trans-(-)-4-(4'-FLUORO PHENYL)-3-[[3,4-(METHYLENEDIOXY)- PHENOXY]-METHYL]-N-METHYLPIPERIDINE", u'AB1004560', u'TC-063875', u'TL8000322', u'FT-0642703', u'M2645', u'429M362', u'C-20414', u'J-002423', u'BRD-K19277754-001-01-4', u'(-)-trans-4-(4-Fluorophenyl)-3-(3,4-methylenedioxyphenoxymethyl)-1-methylpiperidine', u'(3S,4R)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-1-methylpiperidine', u'(3S,4R)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)-1-methylpiperidine', u"(3S,4R)-3-(3,4-Methylene-dioxyphenoxy-methyl)-4-(4'-fluorophenyl)-N-methylpiperidine", u'(3S,4R)-3-[(2H-1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-1-methylpiperidine', u'Paroxetine Related Compound F, United States Pharmacopeia (USP) Reference Standard', u'trans(-)-1-Methyl-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine', u'N-Methylparoxetine; (3S-trans)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-1-methyl-Piperidine; (-)-trans-4-(4-Fluorophenyl)-3-(3,4-methylenedioxyphenoxymethyl)-1-methylpiperidine', u'paroxetine', u'METHYL PAROXETINE', u'CID10947895', u'S-7965', u'Piperidina, 3-[(1,3-benzodioxol-5-iloxi)metil]-4-(4-fluorofenil)-1-metil-, (3s,4r)-']
- (-)-trans-4-(4-Fluorophenyl)-3-(3,4-methylenedioxyphenoxymethyl)-1-methylpiperidine
- (3S,4R)-3-(3,4-Methylene-dioxyphenoxy-methyl)-4-(4'-fluorophenyl)-N-methylpiperidine
- (3S,4R)-3-[(1,3-Benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-1-methylpiperidine
- 3-[(1,3-Benzodioxol-5-Yloxy)Methyl]-4-(4-Fluorophenyl)-1-Methylpiperidine
- N-Methylparoxetine
- PAR-Me
- Piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-1-methyl-, (3S,4R)-
- Piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-1-methyl-, (3S-trans)-
Avis:
Nos produits sont destinés uniquement à un usage en laboratoire. Pour tout autre usage, veuillez nous contacter.
Marque:
Indagoo
Stockage à long terme :
Notes :
Propriétés chimiques
Masse moléculaire :
343.3920
Formule :
C20H22FNO3
Degré de pureté :
98%
Couleur/Forme :
Solid
InChI :
InChI=1S/C20H22FNO3/c1-22-9-8-18(14-2-4-16(21)5-3-14)15(11-22)12-23-17-6-7-19-20(10-17)25-13-24-19/h2-7,10,15,18H,8-9,11-13H2,1H3/t15-,18-/m0/s1
Code InChI :
MOJZPKOBKCXNKG-YJBOKZPZSA-N
MDL:
Point de fusion :
Point d'ébullition :
Point d'éclair :
Densité :
Concentration :
EINECS :
Merck :
Code SH :
